POONGJEON PHARMACY CO.,LTD.
Founded 2014, KOSDAQ-listed 2020, Poongjeon Pharmacy develops stem cell therapies, sells Iroro/Dermassimo cosmetics, runs pharma wholesale.
Price
Change
Market cap
Business overview
Source: DART corporate disclosurePoongjeon Pharmacy was founded in 2014 and listed on KOSDAQ as a technology growth company in June 2020. It develops stem cell therapeutics SCM-CGH and SCM-AGH via its subfractionation culturing method, sells hair and skin products under the Iroro and Dermassimo brands, and runs a pharmaceutical wholesale business. It holds a clinical-approval and exclusive-distribution agreement with Malaysia's Duopharma Biotech Berhad covering Malaysia, Singapore, Brunei and the Philippines, absorbed Dermassimo Co., Ltd. on November 25, 2025, and supplies prescription drugs to hospitals such as Chung-Ang University Hospital and Gangnam Severance Hospital and via Public Procurement Service tenders.
Products & technology
- Iroro Dearscalp hair productsMen's and women's shampoo, treatment, tonic, and serum using stem cell culture medium (CXCL1)
- Iroro Nuvon skin productsMulti serum, body lotion, and AD intensive cream using stem cell culture medium for skin soothing
- DermassimoHair-loss relief ampoule and men's/women's shampoo using Redensyl ingredient
- Prescription drug wholesale supplySupply of prescription drugs and narcotics (pain management) to major hospitals and via Public Procurement Service tenders
R&D and key agreements
Source: DART corporate disclosureSCM-CGH · 만성 이식편대숙주질환 · Stem cell therapeutic based on subfractionation culturing method
SCM-AGH · 중등증-중증 급성 췌장염 · Stem cell therapeutic based on subfractionation culturing method
SCM-AGH · 중등증-중증 아토피 피부염 · Stem cell therapeutic based on subfractionation culturing method
Key disclosures
KRX KIND via OpenDARTShow 3 more events
Patents
KIPRIS · applicant-matchedRegistered · 2024-12 · Application 1020240180763
Registered · 2024-11 · Application 1020240168072
Registered · 2024-07 · Application 1020240098531
Registered · 2024-07 · Application 1020240098532
Registered · 2024-03 · Application 1020240034118
Published · 2022-09 · Application 1020247014665
Rejected · 2022-06 · Application 1020220072890
Abandoned · 2021-06 · Application 1020210070810
Registered · 2021-05 · Application 1020210064147
Registered · 2020-12 · Application 1020200181940
Show 14 more patents
Registered · 2020-03 · Application 1020200033112
Registered · 2020-01 · Application 1020200001466
Registered · 2019-12 · Application 1020217018024
Registered · 2019-12 · Application 1020190159950
Registered · 2019-12 · Application 1020190159866
Registered · 2019-05 · Application 1020190061179
Registered · 2019-05 · Application 1020190051596
Registered · 2017-11 · Application 1020170146906
Registered · 2017-08 · Application 1020170100314
Expired · 2017-02 · Application 1020170024766
Registered · 2016-09 · Application 1020160115081
Registered · 2016-08 · Application 1020160100966
Expired · 2016-08 · Application 1020160100969
Registered · 2015-07 · Application 1020150107319
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- AnthropicClaudeBot2
- MicrosoftBingbot1
- PerplexityPerplexityBot1
- OpenAIOAI-SearchBot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Sep 30, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for POONGJEON PHARMACY CO.,LTD. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition